🔗 Share this article

Given that the United States continues making historic adjustments to its vaccine recommendations, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 shots during the global health crisis and has focused upon potential deaths after COVID-19 immunization in her short time at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Health officials planned to reveal radical revisions to the childhood immunization program recently, synchronizing the US with the Danish vaccine program, it is understood – a major change that would put the US out of alignment with much of the world with little proof for public health gain. The announcement has been postponed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to head the center this year.

A Shift at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain pediatric shot schedules in the US in order to be more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccination policy – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no obvious track record in medication creation, regulation or administrative roles, which has been typical for former heads of the CBER. She has been employed at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have the requisite experience” for running the CDER, stated Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a sizeable institution. She lacks background in industry regulation.”

Former commissioners of CBER would “grasp regulatory frameworks and the underlying principles of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that former directors who ran the center have had.”

The drug center has an vast range of responsibilities at the agency, she emphasized.

“Many people just pays attention on the new drug program, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and more, and every single one must be supervised,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a major management component to the job, which oversees more than 5,000 employees. “It is a massive leadership role, if you perform it correctly,” Woodcock concluded.

Official Statement and Disputed Initiatives

In response to questions about Dr. Høeg's credentials and whether this selection signifies increased cooperation among agency officials on vaccines, a spokesperson responded that the “inquiries are based on incorrect presumptions”.

“This background matches the duties of her position,” the spokesperson stated, pointing to the months Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg takes over the agency head's recently launched expedited review system, a controversial one-day therapy clearance system that reportedly worried her predecessors. “By what process are these therapies being selected for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of secrecy happening at the agency right now.”

In general, he said, “the FDA looks to be trending towards more relaxed regulations of pharmaceuticals, except for immunizations.”

Public History on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, some experts observe. She released a study using non-validated public submissions to determine the rate of myocarditis after Covid immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are riskier than they are.

Part of her “desired changes” for the incoming federal leadership included changing rules for new vaccines and halting “optional” vaccines, she stated post-election on a online show. At the agency, Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her preconceived notions and tailors the evidence to fit the evidence in a highly disingenuous, fraudulent way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|